Effect of Qushi Kangai formula for recurrence and metastasis rate in patients with stage II / III colon cancer after adjuvant chemotherapy:A Pilot Trial.
- Conditions
- Colon cancer
- Registration Number
- ITMCTR2200005510
- Lead Sponsor
- Guangdong Provincial Hospital of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Patients have been diagnosed with colon cancer by histopathology or cell pathology;
(2) Postoperative pathological stage is high-risk stage II / III;
(3) Completion of Adjuvant Chemotherapy;
(4) The distance from the last chemotherapy to the enrollment time = 3 months;
(5) PS score (ECOG) = 2;
(6) Age:18 to 75 years old;
(7) Normal liver and kidney function;
(8) Sign the informed consent form, the patient is willing to accept the treatment of this scheme, can adhere to the medication and has good compliance.
(1) Unable to complete the baseline evaluation form;
(2) Intestinal obstruction or incomplete intestinal obstruction;
(3) Complicated with other serious diseases, including uncontrolled active infection, serious electrolyte disorder and bleeding tendency;
(4) Pregnant and lactating women;
(5) Patients with depression, mania, obsessive-compulsive disorder and schizophrenia;
(6) Have a history of autoimmune diseases, blood system diseases and organ transplantation, and use hormones or immunosuppressants for a long time;
(7) Combined with other uncontrolled tumors;
(8) Patients who have been received neoadjuvant radiotherapy before operation or intended to receive radiotherapy;
(9) Serious brain disease or mental disease affecting the patient's ability of private prosecution;
(10) History of organ transplantation (including bone marrow autotransplantation and peripheral stem cell transplantation);
(11) No legal capacity, medical or ethical reasons affect the continuation of the research.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence and metastasis rate;
- Secondary Outcome Measures
Name Time Method Dampness syndrome scale;Circulating tumor DNA(ctDNA);Circulating Tumor Cell(CTC) count;